NASDAQ / LIVE COMPANY INTELLIGENCE

Aclaris Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERACRS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ACRS COVERAGE

What’s moving Aclaris Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Investors are testing whether Aclaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Aclaris Therapeutics, Inc. Added to Russell 3000 and Russell 2000 Indexes Following 2025 Annual Reconstitution

Aclaris Therapeutics, Inc. Added to Russell 3000 and Russell 2000 Indexes Following 2025 Annual Reconstitution

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Is Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds?

Is Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds?

The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ACRS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-06 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-04SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗8-KMaterial company eventFiled 2026-04-28 · Period 2026-04-28SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-23 · Period 2026-06-04SEC ↗4Official SEC filingFiled 2026-06-08 · Period 2026-06-04SEC ↗
EARNINGS / QUARTERLY TRACKER

Aclaris Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.